– New data describe the first structure of anellovirus particles, including a novel jelly roll domain architecture – – Structural...
SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology...
Arctic Vision also licensed and is developing Eyenovia’s programs for pediatric progressive myopia (MicroPine) and pharmacologic mydriasis (MydCombi™) in Greater...
Court Denies JDS1’s Motion for Expedited Proceedings Board Reiterates Commitment to Distributing Cash to Stockholders Once Potential Liability and Expenses...
CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare...
MARKHAM, Ontario, July 06, 2022 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it...
TUCSON, Ariz., July 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...
WATERTOWN, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated...
VANCOUVER, British Columbia, July 06, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in...
Peer-reviewed study data suggest CEND-1, in combination with gemcitabine and nab-paclitaxel, demonstrates favorable safety and tolerability along with encouraging efficacyBASKING...
Researchers conducted exploratory analysis to find an optimized IO score after validation of original established endpoint was presented at the...
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will...
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will...
ORANGE, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled...
RoxyBond is the first and only immediate-release opioid medication with FDA-approved labeling describing abuse-deterrent properties.1 PRINCETON, N.J., July 06, 2022...
Mr. Larsen brings over 40 years of medical device industry experience and skills strongly aligned with the Company’s strategy to...
BELTSVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel,...
- Phase 3 Clinical Study Met Primary and Key Secondary Endpoints - - Primary Endpoint: Sabizabulin Treatment Showed Statistically Significant...
TORONTO, July 06, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"),...